Early ctDNA dynamics and efficacy of lorlatinib in patients with treatment-naïve, advanced, ALK-positive non-small cell lung cancer.
暂无分享,去创建一个
A. Shaw | C. Chiu | P. Tomasini | J. Martini | R. Soo | H. Kim | A. van der Wekken | R. Ferrara | D. Kowalski | A. Polli | A. Calella | F. Toffalorio | S. Teraoka | B. Solomon | D. Shepard